Hedgehog-GLI and Notch Pathways Sustain Chemoresistance and Invasiveness in Colorectal Cancer and Their Inhibition Restores Chemotherapy Efficacy
Open accessThe DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Abstract
Colorectal cancer (CRC) is a leading cause of cancer-related mortality and chemoresistance is a major medical issue. The epithelial-to-mesenchymal transition (EMT) is the primary step in the emergence of the invasive phenotype and the Hedgehog-GLI (HH-GLI) and NOTCH signaling pathways are associated with poor prognosis and EMT in CRC. CRC cell lines harboring KRAS or BRAF mutations, grown as monolayers and organoids, were treated with the chemotherapeutic agent 5-Fluorouracil (5-FU) alone or combined with HH-GLI and NOTCH pathway inhibitors GANT61 and DAPT, or arsenic trioxide (ATO) to inhibit both pathways. Treatment with 5-FU led to the activation of HH-GLI and NOTCH pathways in both models. In KRAS mutant CRC, HH-GLI and NOTCH signaling activation co-operate to enhance chemoresistance and cell motility, while in BRAF mutant CRC, the HH-GLI pathway drives the chemoresistant and motile phenotype. We then showed that 5-FU promotes the mesenchymal and thus invasive phenotype in KRAS and BRAF mutant organoids and that chemosensitivity could be restored by targeting the HH-GLI pathway in BRAF mutant CRC or both HH-GLI and NOTCH pathways in KRAS mutant CRC. We suggest that in KRAS-driven CRC, the FDA-approved ATO acts as a chemotherapeutic sensitizer, whereas GANT61 is a promising chemotherapeutic sensitizer in BRAF-driven CRC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Nevertheless, inhibiting Hh signaling in CRC cells has been shown to be effective in reducing cell viability and expression of CSC markers and may also enhance chemosensitivity at least in some cellular contexts [200,201,202].”
From Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer (2025) · cites this paper as [202]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Notch Signaling: Cell Fate Control and Signal Integration in Development
Artavanis-Tsakonas, S., Rand, M. D., & Lake, R. J. (1999) · Science · doi:10.1126/science.284.5415.770 · Cited by 5,909
Modeling Development and Disease with Organoids
Clevers, H. (2016) · Cell · doi:10.1016/j.cell.2016.05.082 · Cited by 3,196 · cited 1×
“Organoid models in pre-clinical studies have become widespread due to their high reproducibility and high similarity to in vivo models [28,29].”
BackgroundOrganogenesis in a dish: Modeling development and disease using organoid technologies
Lancaster, M. A., & Knoblich, J. A. (2014) · Science · doi:10.1126/science.1247125 · Cited by 2,931 · cited 1×
“Organoid models in pre-clinical studies have become widespread due to their high reproducibility and high similarity to in vivo models [28,29].”
BackgroundGlobal colorectal cancer burden in 2020 and projections to 2040
Xi, Y., & Xu, P. (2021) · Translational Oncology · doi:10.1016/j.tranon.2021.101174 · Cited by 2,434 · cited 1×
“Despite recent advances in cancer therapy, CRC is still among the prevalent causes of cancer-related death [30].”
BackgroundEchelard, Y., Epstein, D. J., St-Jacques, B., Shen, L., Mohler, J., McMahon, J. A., & McMahon, A. P. (1993) · Cell · doi:10.1016/0092-8674(93)90627-3 · Cited by 2,154 · cited 1×
“The HH-GLI pathway has a crucial role in correct embryonic development and plays a role in the physiological maintenance of many tissues, including the colonic mucosa [39,40].”
BackgroundRobust single-particle tracking in live-cell time-lapse sequences
Jaqaman, K., Loerke, D., Mettlen, M., Kuwata, H., Grinstein, S., Schmid, S. L., & Danuser, G. (2008) · Nature Methods · doi:10.1038/nmeth.1237 · Cited by 1,970 · cited 1×
“Frame-to-frame tracking was implemented using the linear assignment problem (LAP) method [22,23].”
MethodTargeting cancer stem cell pathways for cancer therapy
Yang, L., Shi, P., Zhao, G., Xu, J., Peng, W., Zhang, J., Zhang, G., Wang, X., Dong, Z., Chen, F., et al. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0110-5 · Cited by 1,906 · cited 1×
“The previous set of experiments allowed us to point out the role of HH-GLI and NOTCH pathways as regulators of EMT in KRAS mutant and BRAF mutant CRC, a key feature of chemoresistance [27].”
Cervantes, A., Adam, R., Roselló, S., Arnold, D., Normanno, N., Taïeb, J., Seligmann, J., De Baere, T., Osterlund, P., Yoshino, T., et al. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2022.10.003 · Cited by 1,796 · cited 3×
“First-line and palliative treatments for metastatic CRC, bearing KRAS or BRAF mutations, include the cytotoxic chemotherapeutic agent 5-fluorouracil (5-FU) [1,4]; however, patients often present disease recurrence after 5-FU therapy [5].”
BackgroundBitgood, M. J., & McMahon, A. P. (1995) · Developmental Biology · doi:10.1006/dbio.1995.0010 · Cited by 1,370 · cited 1×
“The HH-GLI pathway has a crucial role in correct embryonic development and plays a role in the physiological maintenance of many tissues, including the colonic mucosa [39,40].”
BackgroundNotch signaling pathway: architecture, disease, and therapeutics
Zhou, B., Lin, W., Long, Y., Yang, Y., Zhang, H., Wu, K., & Chu, Q. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00934-y · Cited by 1,114 · cited 1×
“Interestingly, deregulation of the NOTCH pathway was described in numerous cancerous and non-cancerous diseases, with its role being highly context-dependent [14].”
Background5-fluorouracil and other fluoropyrimidines in colorectal cancer: Past, present and future
Vodenkova, S., Buchler, T., Cervena, K., Veskrnova, V., Vodicka, P., & Vymetalkova, V. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.107447 · Cited by 956 · cited 1×
“First-line and palliative treatments for metastatic CRC, bearing KRAS or BRAF mutations, include the cytotoxic chemotherapeutic agent 5-fluorouracil (5-FU) [1,4]; however, patients often present disease recurrence after 5-FU therapy [5].”
BackgroundUnited States Multicenter Study of Arsenic Trioxide in Relapsed Acute Promyelocytic Leukemia
Soignet, S. L., Frankel, S. R., Douer, D., Tallman, M. S., Kantarjian, H., Calleja, E., Stone, R. M., Kalaycio, M., Scheinberg, D. A., Steinherz, P., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.18.3852 · Cited by 826 · cited 1×
“Arsenic Trioxide (ATO) is an organic compound approved for the therapy of adult patients with acute promyelocytic leukemia [25] and was shown to successfully inhibit both HH-GLI and NOTCH pathways [26].”
BackgroundMichalet, X. (2010) · Physical Review E · doi:10.1103/physreve.82.041914 · Cited by 721 · cited 1×
“In the third step, MSD, the mean square distance travelled by a cell given a certain time interval (see Supplementary Figure S3), was computed from single trajectories, as described by Michalet X [24].”
MethodActivation of the PI3K/Akt pathway and chemotherapeutic resistance
West, K. A., Sianna Castillo, S., & Dennis, P. A. (2002) · Drug Resistance Updates · doi:10.1016/s1368-7646(02)00120-6 · Cited by 585 · cited 1×
“One of the mechanisms conferring drug resistance is the misactivation of evolutionarily conserved pathways, such as Wingless (WNT) [31,32], phosphoinositide-3-kinase [33,34], extracellular signal-regulated kinase (ERK) [35,36], nuclear factor-κB (NF-κB) [37,38] and the Hedgehog-GLI (HH-GLI) signaling pathway [20].”
BackgroundMicroenvironmental regulation of stem cells in intestinal homeostasis and cancer
Medema, J. P., & Vermeulen, L. (2011) · Nature · doi:10.1038/nature10212 · Cited by 472 · cited 1×
“Stem cells, transit amplifying cells and terminally differentiated secretory cells or enterocytes, concur in the formation of the structural unit of the colon, known as the crypt of Lieberkuhn [46].”
Background5-FU promotes stemness of colorectal cancer via p53-mediated WNT/β-catenin pathway activation
Cho, Y.-H., Ro, E. J., Yoon, J.-S., Mizutani, T., Kang, D.-W., Park, J.-C., Il Kim, T., Clevers, H., & Choi, K.-Y. (2020) · Nature Communications · doi:10.1038/s41467-020-19173-2 · Cited by 336 · cited 2×
“First-line and palliative treatments for metastatic CRC, bearing KRAS or BRAF mutations, include the cytotoxic chemotherapeutic agent 5-fluorouracil (5-FU) [1,4]; however, patients often present disease recurrence after 5-FU therapy [5].”
BackgroundPietrobono, S., Gagliardi, S., & Stecca, B. (2019) · Frontiers in Genetics · doi:10.3389/fgene.2019.00556 · Cited by 303 · cited 2×
“Activated GLI translocate into the nucleus where they bind to DNA and activate the transcription of target genes [10].”
BackgroundTargeting Nuclear Factor-Kappa B to Overcome Resistance to Chemotherapy
Godwin, P., Baird, A. M., Heavey, S., Barr, M. P., O’Byrne, K. J., & Gately, K. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00120 · Cited by 296
Kumar, V., Vashishta, M., Kong, L., Wu, X., Lu, J. J., Guha, C., & Dwarakanath, B. S. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.650772 · Cited by 255
Tracking in cell and developmental biology
Meijering, E., Dzyubachyk, O., Smal, I., & van Cappellen, W. A. (2009) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2009.07.004 · Cited by 242 · cited 1×
“Frame-to-frame tracking was implemented using the linear assignment problem (LAP) method [22,23].”
MethodDeng, J., Bai, X., Feng, X., Ni, J., Beretov, J., Graham, P., & Li, Y. (2019) · BMC Cancer · doi:10.1186/s12885-019-5824-9 · Cited by 242 · cited 1×
“One of the mechanisms conferring drug resistance is the misactivation of evolutionarily conserved pathways, such as Wingless (WNT) [31,32], phosphoinositide-3-kinase [33,34], extracellular signal-regulated kinase (ERK) [35,36], nuclear factor-κB (NF-κB) [37,38] and the Hedgehog-GLI (HH-GLI) signaling pathway [20].”
BackgroundA Review on Notch Signaling and Colorectal Cancer
Tyagi, A., Sharma, A. K., & Damodaran, C. (2020) · Cells · doi:10.3390/cells9061549 · Cited by 179 · cited 1×
“Both HH-GLI and NOTCH pathways were described as deregulated and associated with poor prognosis in CRC [18,19].”
BackgroundERK is a Pivotal Player of Chemo-Immune-Resistance in Cancer
Salaroglio, I. C., Mungo, E., Gazzano, E., Kopecka, J., & Riganti, C. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20102505 · Cited by 170 · cited 1×
“One of the mechanisms conferring drug resistance is the misactivation of evolutionarily conserved pathways, such as Wingless (WNT) [31,32], phosphoinositide-3-kinase [33,34], extracellular signal-regulated kinase (ERK) [35,36], nuclear factor-κB (NF-κB) [37,38] and the Hedgehog-GLI (HH-GLI) signaling pathway [20].”
BackgroundEberl, M., Klingler, S., Mangelberger, D., Loipetzberger, A., Damhofer, H., Zoidl, K., Schnidar, H., Hache, H., Bauer, H., Solca, F., et al. (2012) · EMBO Molecular Medicine · doi:10.1002/emmm.201100201 · Cited by 165 · cited 1×
“Of note, it was demonstrated that transforming growth factor-beta (TGFβ) [41], epidermal growth factor receptor (EGFR) [42], mitogen-activated protein kinases (MAPK) [11], β-arrestin [43] and WNT/β-catenin [44,45] were able to induce the expression of GLI, regardless of SMO activation.”
BackgroundMorkel, M., Riemer, P., Bläker, H., & Sers, C. (2015) · Oncotarget · doi:10.18632/oncotarget.4750 · Cited by 144 · cited 2×
“BRAF-mutant CRC often displays genome-wide hypermethylation, high microsatellite instability and mutation rates, while KRAS mutant CRC is associated with lower levels of microsatellite instability and gene methylation [2].”
BackgroundWnt Signaling Stimulates Transcriptional Outcome of the Hedgehog Pathway by Stabilizing GLI1 mRNA
Noubissi, F. K., Goswami, S., Sanek, N. A., Kawakami, K., Minamoto, T., Moser, A., Grinblat, Y., & Spiegelman, V. S. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-1500 · Cited by 134 · cited 2×
“A recent paper showed that the HH-GLI blockade with GANT61 was able to inhibit NOTCH and WNT/β-catenin in cellular models of CRC [47].”
BackgroundZhang, K., Zhang, T., Yang, Y., Tu, W., Huang, H., Wang, Y., Chen, Y., Pan, K., & Chen, Z. (2022) · Theranostics · doi:10.7150/thno.73746 · Cited by 132 · cited 1×
“Other mechanisms for resistance to therapy include the inhibition of apoptosis driven by upregulation of autophagy [7], metabolic reprogramming [8], upregulation of molecules involved in drug efflux and drug metabolism and activation of alternative pathways [9].”
BackgroundRole of Wnt/β‐Catenin Signaling in the Chemoresistance Modulation of Colorectal Cancer
Yuan, S., Tao, F., Zhang, X., Zhang, Y., Sun, X., & Wu, D. (2020) · BioMed Research International · doi:10.1155/2020/9390878 · Cited by 131 · cited 4×
“A recent paper showed that the HH-GLI blockade with GANT61 was able to inhibit NOTCH and WNT/β-catenin in cellular models of CRC [47].”
BackgroundInfluentialFrom Gut Homeostasis to Cancer
Radtke, F., Clevers, H. C., & Riccio, O. (2006) · Current Molecular Medicine · doi:10.2174/156652406776894527 · Cited by 121 · cited 2×
“NOTCH signaling has been reported to play a crucial role in the development of the normal mucosa [15] and its aberrant activation is related to carcinogenesis in CRC.”
BackgroundNoncanonical GLI1 signaling promotes stemness features and in vivo growth in lung adenocarcinoma
Pò, A., Silvano, M., Miele, E., Capalbo, C., Eramo, A., Salvati, V., Todaro, M., Besharat, Z. M., Catanzaro, G., Cucchi, D., et al. (2017) · Oncogene · doi:10.1038/onc.2017.91 · Cited by 118 · cited 3×
“In cancers, GLI1 can also be activated in a non-canonical way by the “oncogenic load” of the cancer cell [11].”
BackgroundSelf-citationNF-κB in pancreatic cancer: Its key role in chemoresistance
Li, Q., Yang, G., Feng, M., Zheng, S., Cao, Z., Qiu, J., You, L., Zheng, L., Hu, Y., Zhang, T., et al. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.02.011 · Cited by 107 · cited 1×
“One of the mechanisms conferring drug resistance is the misactivation of evolutionarily conserved pathways, such as Wingless (WNT) [31,32], phosphoinositide-3-kinase [33,34], extracellular signal-regulated kinase (ERK) [35,36], nuclear factor-κB (NF-κB) [37,38] and the Hedgehog-GLI (HH-GLI) signaling pathway [20].”
BackgroundVarnat, F., Siegl‐Cachedenier, I., Malerba, M., Gervaz, P., & Altaba, A. R. I. (2010) · EMBO Molecular Medicine · doi:10.1002/emmm.201000098 · Cited by 106
Li, Z.-N., Zhao, L., Yu, L.-F., & Wei, M.-J. (2020) · Gastroenterology Report · doi:10.1093/gastro/goaa022 · Cited by 104 · cited 1×
“Indeed, KRAS and BRAF mutations occur in 40% and 10% of CRC, respectively [2], and they are both associated with a poor outcome [3].”
BackgroundSun, L., Ke, J., He, Z., Chen, Z., Huang, Q., Ai, W., Wang, G., Wei, Y., Zou, X., Zhang, S., et al. (2017) · Journal of Cancer · doi:10.7150/jca.19142 · Cited by 91 · cited 1×
“Downstream target genes include HES1, which is involved in EMT and transcriptionally regulates ATPbinding cassettes transporters (ABC transporters), involved in multidrug resistance [13].”
BackgroundZhang, J., Fan, J., Zeng, X., Nie, M., Luan, J., Wang, Y., Ju, D., & Yin, K. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2020.10.022 · Cited by 90 · cited 1×
“Both HH-GLI and NOTCH pathways were described as deregulated and associated with poor prognosis in CRC [18,19].”
BackgroundMitogen-Activated Protein Kinases and Chemoresistance in Pancreatic Cancer Cells
Zhao, Y., Shen, S., Guo, J., Chen, H., Greenblatt, D. Y., Kleeff, J. H., Liao, Q., Chen, G., Friess, H., & Leung, P. S. (2006) · Journal of Surgical Research · doi:10.1016/j.jss.2006.06.031 · Cited by 74 · cited 1×
“One of the mechanisms conferring drug resistance is the misactivation of evolutionarily conserved pathways, such as Wingless (WNT) [31,32], phosphoinositide-3-kinase [33,34], extracellular signal-regulated kinase (ERK) [35,36], nuclear factor-κB (NF-κB) [37,38] and the Hedgehog-GLI (HH-GLI) signaling pathway [20].”
BackgroundSignificance of Notch and Wnt signaling for chemoresistance of colorectal cancer cells HCT116
Kukcinaviciute, E., Jonusiene, V., Sasnauskiene, A., Dabkeviciene, D., Eidenaite, E., & Laurinavicius, A. (2018) · Journal of Cellular Biochemistry · doi:10.1002/jcb.26783 · Cited by 69 · cited 4×
“A recent paper showed that the HH-GLI blockade with GANT61 was able to inhibit NOTCH and WNT/β-catenin in cellular models of CRC [47].”
BackgroundInfluentialChen, J., Na, R., Xiao, C. W., Wang, X., Wang, Y., Yan, D., Song, G., Liu, X., Chen, J., Lu, H., et al. (2021) · Oncogene · doi:10.1038/s41388-021-01815-4 · Cited by 68 · cited 1×
“Other mechanisms for resistance to therapy include the inhibition of apoptosis driven by upregulation of autophagy [7], metabolic reprogramming [8], upregulation of molecules involved in drug efflux and drug metabolism and activation of alternative pathways [9].”
BackgroundMiele, E., Pò, A., Begalli, F., Antonucci, L., Mastronuzzi, A., Marras, C. E., Carai, A., Cucchi, D., Abballe, L., Besharat, Z. M., et al. (2017) · BMC Cancer · doi:10.1186/s12885-017-3477-0 · Cited by 67 · cited 1×
“Of note, it was demonstrated that transforming growth factor-beta (TGFβ) [41], epidermal growth factor receptor (EGFR) [42], mitogen-activated protein kinases (MAPK) [11], β-arrestin [43] and WNT/β-catenin [44,45] were able to induce the expression of GLI, regardless of SMO activation.”
BackgroundSelf-citationPò, A., Citarella, A., Catanzaro, G., Besharat, Z. M., Trocchianesi, S., Gianno, F., Sabato, C., Moretti, M., Smaele, E. D., Vacca, A., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-70871-9 · Cited by 62 · cited 5×
“In this context, our previous work has described a chemoresistance mechanism operated by the HH-GLI signaling in CRC, where chemotherapy treatment resulted in aberrant activation of the HH-GLI pathway which in turn led to the transcription of ATP-binding cassette transporters (ABC transporters), involved in multidrug…”
BackgroundInfluentialSelf-citationCelano, M., Schenone, S., Cosco, D., Navarra, M., Puxeddu, E., Racanicchi, L., Brullo, C., Varano, E., Alcaro, S., Ferretti, E., et al. (2008) · Endocrine Related Cancer · doi:10.1677/erc-07-0243 · Cited by 61 · cited 1×
“Lysates were separated on 8% acrylamide gel and immunoblotted using standard procedures [21].”
MethodSelf-citationChen, L., Yang, F., Chen, S., & Tai, J. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.995882 · Cited by 60 · cited 1×
“Chemoresistance is conferred by a plethora of mechanisms, including the modulation of signaling pathways involved in the emergence of the cancer stem features and epithelial-to-mesenchymal transition (EMT) [6].”
BackgroundArsenic trioxide inhibits Hedgehog, Notch and stem cell properties in glioblastoma neurospheres
Ding, D., Lim, K. S., & Eberhart, C. G. (2014) · Acta Neuropathologica Communications · doi:10.1186/2051-5960-2-31 · Cited by 52
Kerl, K., Moreno, N., Holsten, T., Ahlfeld, J., Mertins, J., Hotfilder, M., Kool, M., Bartelheim, K., Schleicher, S., Handgretinger, R., et al. (2014) · International Journal of Cancer · doi:10.1002/ijc.28719 · Cited by 45 · cited 2×
“Of note, data n the muta ional status of enrolled patients re not available [48,49].”
BackgroundMarín, J. J. G., Macías, R. I. R., Monte, M. J., Herráez, E., Peleteiro‐Vigil, A., de Blas, B. S., Sanchon-Sanchez, P., Temprano, Á. G., Espinosa-Escudero, R. A., Lozano, E., et al. (2020) · Cancers · doi:10.3390/cancers12092605 · Cited by 44 · cited 1×
“Other mechanisms for resistance to therapy include the inhibition of apoptosis driven by upregulation of autophagy [7], metabolic reprogramming [8], upregulation of molecules involved in drug efflux and drug metabolism and activation of alternative pathways [9].”
BackgroundArdalan, B., Subbarayan, P. R., Ramos, Y., Gonzalez, M., Fernández, A., Mezentsev, D., dos Reis, I. M., DUNCAN, R. C., Podolsky, L., Lee, K. P., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2590 · Cited by 42 · cited 2×
“Of note, data n the muta ional status of enrolled patients re not available [48,49].”
BackgroundJacobs, C. T., & Huang, P. (2019) · eLife · doi:10.7554/elife.49252 · Cited by 38
de Reyniès, A., Javelaud, D., Elarouci, N., Marsaud, V., Gilbert, C., & Mauviel, A. (2020) · Scientific Reports · doi:10.1038/s41598-020-71559-w · Cited by 18
Si, Y., Li, L., Zhang, W., Liu, Q., & Liu, B. (2022) · Oncology Reports · doi:10.3892/or.2022.8397 · Cited by 13
Cited by
Notch signaling pathway in cancer: from mechanistic insights to targeted therapies
Shi, Q., Xue, C., Zeng, Y., Yuan, X., Chu, Q., Jiang, S., Wang, J., Zhang, Y., Zhu, D., & Li, L. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01828-x · Cited by 401
Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer
Haynes, J., & Manogaran, P. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26051988 · Cited by 82
“Nevertheless, inhibiting Hh signaling in CRC cells has been shown to be effective in reducing cell viability and expression of CSC markers and may also enhance chemosensitivity at least in some cellular contexts [200–202].”
Arsenic trioxide: applications, mechanisms of action, toxicity and rescue strategies to date
Yan, M., Wang, H., Wei, R., & Li, W. (2023) · Archives of Pharmacal Research · doi:10.1007/s12272-023-01481-y · Cited by 59
Epithelial–mesenchymal plasticity in cancer: signaling pathways and therapeutic targets
Wang, X., Xue, X., Pang, M., Yu, L., Qian, J., Li, X., Tian, M., Lü, A., Lu, C. Y., & Liu, Y. (2024) · MedComm · doi:10.1002/mco2.659 · Cited by 60
“123 Moreover, Hippo signaling pathway also participates in the modulation of EMT, the main effector downstream of which is the YAP.”
BackgroundThe Impact of Cancer Stem Cells in Colorectal Cancer
Radu, P., Zurzu, M., Tigora, A., Paic, V., Bratucu, M., Garofil, D., Surlin, V., Munteanu, A. C., Coman, I. S., Popa, F., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25084140 · Cited by 30
Metadata
- Authors
- Citarella, A., Catanzaro, G., Besharat, Z. M., Trocchianesi, S., Barbagallo, F., Gosti, G., Leonetti, M., Di Fiore, A., Coppola, L., Autilio, T. M., Spinello, Z., Vacca, A., De Smaele, E., Venneri, M. A., Ferretti, E., Masuelli, L., & Po, A.
- Affiliations
- Sapienza University of Rome (IT)
- Università degli Studi di Enna Kore (IT)
- Italian Institute of Technology (IT)
- Department of Experimental Medicine, Sapienza University of Rome, Viale Regina Elena 324, 00161 Rome, Italy
- Department of Molecular Medicine, Sapienza University of Rome, Viale Regina Elena 291, 00161 Rome, Italy
- ORCID
- Venue
- Cancers
- Publisher
- MDPI AG
- Published
- 2023-02-25
- Volume
- 15
- Issue
- 5
- Pages
- 1471
- ISSN
- 2072-6694 (ISSN-L)
- PMC
- PMC10000782
- OpenAlex
- W4322502598
- Cited by
- 27
- References
- 49
- Citations by year
- 2026: 7 · 2025: 8 · 2024: 8 · 2023: 4
- FWCI
- 2.41
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Cancers (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion, cc-by)
- Funders
- Sapienza University of Rome (2021, RM12117A7F986146, 20203AMKTW, A0375-2020-36549)
- Sapienza Ateneo 2021 (2021, RM12117A7F986146, 20203AMKTW, A0375-2020-36549)
- Istituto Pasteur Italia—Fondazione Cenci Bolognetti (2021, RM12117A7F986146, 20203AMKTW, A0375-2020-36549)
- Project LOCALSCENT (2021, RM12117A7F986146, 20203AMKTW, A0375-2020-36549)
- Call POR-FESR “Gruppi di Ricerca 2020” (2021, RM12117A7F986146, 20203AMKTW, A0375-2020-36549)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Hedgehog Signaling Pathway Studies
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Wnt/β-catenin signaling in development and cancer
- Keywords
- colorectal cancer, chemoresistance, Hedgehog-Gli signaling, Notch signaling, epithelial-mesenchymal transition, tumor invasion, 5-fluorouracil, GANT61, DAPT, arsenic trioxide, KRAS mutation, BRAF mutation, colorectal organoids, chemosensitization, cell motility
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.